Corporate News: MeVis publishes figures for fiscal year 2021/2022 and forecast for 2022/2023

  • Revenues increased by € 2.6 million to € 18.8 million
  • EBIT of € 7.9 million, 42 % margin
  • Earnings after taxes up by € 3.3 million to € 7.8 million
  • Forecast for fiscal 2022/2023
    • Stable revenues of € 18.0 million to € 18.5 million
    • EBIT down to € 4.5 million to € 5.0 million

Bremen, January 27, 2023 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading medical imaging software company, announces its results for the fiscal year 2021/2022, with reporting period October 1, 2021 to September 30, 2022.

Revenues in the past fiscal year 2021/2022 amounted to € 18.8 million (compared to € 16.2 million in fiscal year 2020/2021). Of the revenues, 28 % (previous year: 30 %) were generated from the sale of licenses, 32 % (previous year: 34 %) from maintenance revenues, and 40 % (previous year: 36 %) from other revenues, which include, among other things, services for and recharges to affiliated companies and the parent company.

The year-on-year improvement in revenue from licenses and maintenance is mainly attributable to the sharp rise in the average USD exchange rate, as most invoices are issued in USD. Licenses sold were almost stable. The year-on-year improvement in other revenue is due to an increase in revenue from development services.

The results are very satisfactory. EBIT (earnings before interest and taxes) of € 7.9 million was generated in 2021/2022, compared with € 4.6 million in 2020/2021. The EBIT margin improved accordingly to 42 % compared with the prior-year figure of 28 %.

As a result of the fiscal unity, only minor income taxes of € 0.1 million were incurred in the past fiscal year, identical to the previous year.

This results in earnings after taxes of € 7.8 million (41 % margin) for the financial year 2021/2022, compared to € 4.5 million (28 % margin) in 2020/2021. The profit of € 7,789k will be transferred to Varex Imaging Deutschland AG on the basis of the control and profit transfer agreement.

For the financial year 2022/2023, sales are now expected to remain almost stable compared to the previous year at € 18.0 million to € 18.5 million. In addition to stable sales with the customer Hologic, only slightly increasing sales revenues are expected in the lung and liver segments. We expect a slight decline in the area of development services. For earnings before interest and taxes (EBIT), we expect a decline in the range of € 4.5 million to € 5.0 million. The forecast stability in sales and the simultaneous increase in personnel costs, in addition to a significant negative result from exchange rate differences, is the main driver for the EBIT outlook.

The half-year financial report for fiscal year 2022/2023 will be published on May 25, 2023.